Mepolizumab therapy in patients with EGPA

ReferenceStudy designNumber of patientsDose and route of administrationResults
Kahn et al. [30], 2010Case report1750 mg IV monthlyBlood eosinophil normalization
Clinical remission
Chest tomography normalization
Exacerbation reduction
Kim et al. [31], 2010Open-label pilot study7750 mg IV monthlyCS reduction
Reduce eosinophil counts
Clinical stability
Exacerbation reduction
Lack of improvement in pulmonary function
Hermann et al. [32], 2012Case report10750 mg IV monthly9 Patients achieve clinical remission
Decrease eosinophil count
Exacerbation reduction
Potential use to maintain remission in EGPA
CS reduction
Wechsler et al. [24], 2017Multicenter, double-blind, parallel-group, phase III trial136300 mg SC monthlySignificantly weeks (≥ 24 weeks) of remission than placebo (28% vs. 3%)
The reduction of prednisone was 44% in mepolizumab and 7% in the placebo
FDA authorization of 300 mg SC mepolizumab every 4 weeks as the first drug to be approved explicitly for EGPA
Steinfeld et al. [33], 2019Analysis posthoc-300 mg SC monthlyPatients in the mepolizumab group reduce CS intake (78% vs. 32%)
87% Of patients experience no EGPA relapses vs. 53% in the placebo group
Carminati et al. [34], 2021Real-life observational study16100 mg SC monthlyCS reduction
ACT score improvement
Exacerbation reduction
No statistically significant differences in blood eosinophil reduction and pulmonary function
Özdel Öztürk et al. [35], 2022Single-center retrospective real-life study25100 mg SC monthlyCS reduction
ACT score, SNOT-22, and quality of life improvement.
Exacerbation reduction
Reduce eosinophils counts
Improve lung function
Bettiol et al. [36], 2022Multicenter observational study203100 mg SC monthly vs. 300 mg monthlyReduction in BVAS score
CS reduction
Reduce eosinophil counts
No significant differences between 100 mg and 300 mg dose

SNOT: sinonasal outcome test; -: blank cell